Nexstim Bilan de santé

Santé financière contrôle des critères 4/6

Nexstim possède un total de capitaux propres de €1.9M et une dette totale de €6.3M, ce qui porte son ratio d'endettement à 337.9%. Son actif total et son passif total sont €11.2M et de €9.3M.

Informations clés

337.9%

Ratio d'endettement

€6.31m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	€3.03m
Fonds propres	€1.87m
Total du passif	€9.32m
Total des actifs	€11.19m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 5NX ( €6.7M ) dépassent ses passifs à court terme ( €4.5M ).

Passif à long terme: Les actifs à court terme de 5NX ( €6.7M ) dépassent ses passifs à long terme ( €4.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 5NX ( 175.6% ) est considéré comme élevé.

Réduire la dette: 5NX avait des capitaux propres négatifs il y a 5 ans, mais ils sont désormais positifs et se sont donc améliorés.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 5NX dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: Données insuffisantes pour déterminer si 5NX dispose de suffisamment de piste de trésorerie si son flux de trésorerie disponible continue de croître ou de diminuer en fonction des taux historiques.

Nexstim Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Recent updates

Nexstim Plc to Report Fiscal Year 2024 Results on Feb 27, 2025

Nexstim plc Receives Approval from Health Canada for the Marketing and Commercial Distribution of Its NBS 6 System for the Treatment of Major Depressive Disorder

Nexstim Plc Updates Earnings Guidance for the Year 2023

Nexstim Plc, Annual General Meeting, Mar 28, 2024

Nexstim Plc to Report Fiscal Year 2023 Final Results on Mar 06, 2024

Nexstim Plc Releases New System Functionalities for Research Use in Europe

Nexstim Plc to Report Q3, 2023 Results on Oct 27, 2023

Nexstim plc Announces Board Appointments

Nexstim Plc to Report Fiscal Year 2023 Results on Feb 27, 2024

Nexstim plc Provides Overview of Pilot Study Results in Treatment of Severe Depression with Nexstim Nbt®? System At Kuopio University Hospital

Nexstim Applies for Delisting Regarding the Secondary Listing of its Shares from Nasdaq First North Growth Market Sweden

Nexstim Plc, Annual General Meeting, Mar 31, 2023

Nexstim Reports Excellent Treatment Outcomes of over 400 MDD Patients in Patient Registry

Nexstim plc Appoints Tero Weckroth as A New Member of the Nomination Committee

First half 2022 earnings released

Nexstim Plc Provides Earnings Guidance for the Year 2022

High number of new and inexperienced directors

High number of new and inexperienced directors

Forecast to breakeven in 2022

Full year 2021 earnings: Revenues exceed analyst expectations

Nexstim Reaches Over 300 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

Nexstim Plc Announces Results of the Pilot Study in Chronic Pain Treatment At Helsinki University Hospital

Nexstim Plc Receives System Orders from Existing Hospital Customers in Finland

Nexstim Announces Continuation of Pilot Study in Treatment of Severe Depression at Kuopio University Hospital

First half 2021 earnings released: €0.17 loss per share (vs €1.25 loss in 1H 2020)

Nexstim Plc Provides Update on Pilot Study in Chronic Pain Treatment at Helsinki University Hospital

Nexstim Plc Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater Than 50%

Nexstim Plc Granted Authorization for Commercial Distribution of NBS System in Australia

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

Nexstim plc Receives Two NBS System Orders from Hospitals in Norway and the Us

Nexstim plc Provides Encouraging Results of the Initial Pilot Study in Severe Depression At Kuopio University Hospital

Full year 2020 earnings released

Revenue beats expectations

German University Hospital Orders Nexstim NBS System with NexSpeech

Rohan Hoare and Tomas Holmberg No Longer Be Available to Nexstim Plc's Board of Directors for the Period 2021-2022

Nexstim plc Receives Three New NBS System Orders

Nexstim Plc Receives Two New NBT® System Purchase Orders in the United States

Nexstim plc Provides an Update on the Pilot Study in Severe Depression At Kuopio University Hospital

Nexstim Plc Receives an Order and Signs Purchase Agreement to Develop Two Prototype Systems Enabling Introduction of Novel Research Tool for Probing and Diagnosing the Brain

Nexstim plc Continues to Report Promising Results in Quickly Growing Number of Patients Completing SmartFocus rTMS Treatment of Major Depressive Disorder

Pilot Study for New Depression Treatment Protocol with Nexstim NBT® System Starts in Kuopio University Hospital

Nexstim plc Receives Two Nbs System Upgrade Orders in the United States

Earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines